)
Actinium Pharmaceuticals (ATNM) investor relations material
Actinium Pharmaceuticals Investor presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investment thesis and strategic positioning
Differentiated radiotherapy pipeline shaped by deep disease biology understanding, with key 2026 data readouts and cash runway into 2028 ($42.1M cash, no debt, 31.4M shares outstanding).
Two solid tumor assets (ATNM-400, Actimab-A MDSC) target pan-cancer opportunities, including prostate, lung, and breast cancer.
Hematology and conditioning franchise is late-stage and partner-ready, addressing the full AML treatment journey and cell/gene therapy conditioning.
Robust R&D, expanding in-house manufacturing (operational 2H 2026), and strong IP portfolio (~250 patents, including Ac-225 production technology).
Radiopharma landscape and market opportunity
$17B in recent M&A by Big Pharma has left large radiotherapy infrastructure but sparse pipelines, creating demand for novel assets.
Industry pipeline dominated by three targets (PSMA, SSTR2, FAP), with innovation gap and underutilized manufacturing capacity.
Over $10B invested in novel and differentiated radiotherapy platforms since 2024.
Pipeline overview and development stages
Transformative pipeline spans solid tumors (ATNM-400, Actimab-A MDSC), hematology (Actimab-A, lomab-B), and conditioning (lomab-ACT).
Programs range from preclinical to Phase 3, targeting high-value indications and seeking collaborators for expansion.
- Multiple first-in-class radiotherapies advance toward key 2026 data, targeting major oncology markets.ATNM
Investor presentation18 May 2026 - Q1 2026 net loss improved to $5.5M; pipeline advances offset by regulatory and litigation risks.ATNM
Q1 20268 May 2026 - Multiple first-in-class radiotherapies advance toward pivotal data and partnerships in 2026.ATNM
Investor presentation9 Apr 2026 - Net loss improved to $33.9M in 2025 as R&D costs fell, but no commercial revenue was generated.ATNM
Q4 202530 Mar 2026 - Key clinical and R&D advances position the pipeline for major milestones and data in 2025.ATNM
15th Annual LD Micro Invitational 202527 Dec 2025 - Annual Meeting to elect directors and ratify auditor, with focus on governance and risk oversight.ATNM
Proxy Filing2 Dec 2025 - Advancing targeted radiotherapy pipeline with strong data, market reach, and financial runway.ATNM
Life Sciences Investor Forum15 Nov 2025 - Net loss narrowed on lower expenses; focus shifts to solid tumor radiotherapies amid regulatory risks.ATNM
Q3 202514 Nov 2025 - Proxy covers director elections, auditor ratification, and executive pay votes, with focus on governance.ATNM
Proxy Filing5 Nov 2025
Next Actinium Pharmaceuticals earnings date
Next Actinium Pharmaceuticals earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)